206 related articles for article (PubMed ID: 20439625)
1. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.
Abès R; Gélizé E; Fridman WH; Teillaud JL
Blood; 2010 Aug; 116(6):926-34. PubMed ID: 20439625
[TBL] [Abstract][Full Text] [Related]
2. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
3. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
4. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
Funakoshi S; Longo DL; Murphy WJ
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
6. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.
Shrikant P; Khoruts A; Mescher MF
Immunity; 1999 Oct; 11(4):483-93. PubMed ID: 10549630
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
[TBL] [Abstract][Full Text] [Related]
8. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts.
Ghetie MA; Crank M; Kufert S; Pop I; Vitetta E
J Immunother; 2006; 29(5):536-44. PubMed ID: 16971809
[TBL] [Abstract][Full Text] [Related]
9. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
10. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
Gillies SD; Lan Y; Williams S; Carr F; Forman S; Raubitschek A; Lo KM
Blood; 2005 May; 105(10):3972-8. PubMed ID: 15692062
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
Xuan C; Steward KK; Timmerman JM; Morrison SL
Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
[TBL] [Abstract][Full Text] [Related]
14. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.
Tutt AL; O'Brien L; Hussain A; Crowther GR; French RR; Glennie MJ
J Immunol; 2002 Mar; 168(6):2720-8. PubMed ID: 11884438
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
[TBL] [Abstract][Full Text] [Related]
16. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
Xiu Y; Wong CP; Bouaziz JD; Hamaguchi Y; Wang Y; Pop SM; Tisch RM; Tedder TF
J Immunol; 2008 Mar; 180(5):2863-75. PubMed ID: 18292508
[TBL] [Abstract][Full Text] [Related]
17. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
Li B; Shi S; Qian W; Zhao L; Zhang D; Hou S; Zheng L; Dai J; Zhao J; Wang H; Guo Y
Cancer Res; 2008 Apr; 68(7):2400-8. PubMed ID: 18381448
[TBL] [Abstract][Full Text] [Related]
18. Notch2 signaling is required for potent antitumor immunity in vivo.
Sugimoto K; Maekawa Y; Kitamura A; Nishida J; Koyanagi A; Yagita H; Kojima H; Chiba S; Shimada M; Yasutomo K
J Immunol; 2010 May; 184(9):4673-8. PubMed ID: 20351182
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of T-2 toxin-conjugated monoclonal antibody to murine thymoma.
Ohtani K; Murakami H; Shibuya O; Kawamura O; Ohi K; Chiba J; Otokawa M; Ueno Y
Jpn J Exp Med; 1990 Apr; 60(2):57-65. PubMed ID: 2384978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
